Farletuzumab ecteribulin

Farletuzumab ecteribulin (MORAb-202) is an antibody-drug conjugate (ADC), consisting of the humanized anti-human folate receptor alpha (FRα) antibody Farletuzumab conjugated via reduced interchain disulfide bonds to Mal-PEG2-Val-Cit-PAB-eribulin. Farletuzumab ecteribulin has a Drug-to-antibody ratio (DAR) of 4.0. Farletuzumab ecteribulin is highly cytotoxic to FRA-positive cells in vitro. Farletuzumab ecteribulin has potent antitumor activity. This product is for research use only.

Product Details
Species Reactivity	Human
Type	Antibody-drug conjugate
ADC antibody	Farletuzumab (anti-FRα)
ADC cytotoxin (drug)	MMAE
Immunogen	Human folate receptor alpha (FRα)
DAR (Drug to Antibody Ratio)	4
Purity	99%
Molecular Weight	149kDa
Storage Condition	Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.
Storage Buffer	1xPBS